Can neoadjuvant chemoradiotherapy before lateral pelvic lymph node dissection improve local control and prognosis in rectal cancer patients with clinically suspected lateral lymph node metastasis? A multicenter lateral node study in China

• Published in: BMC cancer 2024-01, Vol.24 (1), p.115-10, Article 115
• Main Authors: Xie, Zhongshi, Chen, Qichen, Feng, Bo, Jiang, Yujuan, Wang, Xin, Xing, Wei, Liu, Qian
• Format: Article
• Language: English
• Subjects: Cancer; Cancer therapies; Care and treatment; Chemoradiotherapy; Chemotherapy; Colorectal cancer; Development and progression; Diagnosis; Dissection; Hospitals; Laparoscopy; Lateral pelvic lymph node dissection; Local control; Lymph nodes; Lymphatic metastasis; Lymphatic system; Magnetic resonance imaging; Medical prognosis; Metastases; Metastasis; Neoadjuvant chemoradiotherapy; Neoadjuvant therapy; Patient outcomes; Patients; Prognosis; Rectum; Safety; Statistical analysis; Surgery; Surgical outcomes; Survival
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-024-11867-w

Selective lateral pelvic lymph node (LPN) dissection (LPND) following neoadjuvant chemoradiotherapy (nCRT) for rectal cancer is widely recognized. This study aimed to determine the effects of nCRT before LPND on local control and prognosis of rectal cancer patients. Data were retrieved from a prospective database for rectal cancer patients with clinical LPN metastasis receiving total mesorectal excision and LPND at three institutions between January 2012 and December 2019. Selection bias was minimized using propensity score matching (PSM) and short-term and clinical outcomes were compared. Patients (n = 213) were enrolled and grouped as either nCRT (n = 97) or non-nCRT (n = 116). PSM was used to identify 83 matched pairs. In the matched cohort, nCRT patients had a longer operation duration (310.6 vs. 265.0 min, P = 0.001), lower pathological LPN metastasis rate (32.5% vs. 48.2%, P = 0.040), and fewer harvested lymph nodes (22 vs. 25, P = 0.018) compared to the non-nCRT group. However, after PSM, the two groups had similar estimated overall 3-year survival (79.5% vs. 80.7%, P = 0.922), 3-year disease-free survival (66.1% vs. 65.5, P = 0.820), and 3-year local recurrence-free survival (88.6% vs. 89.7%, P = 0.927). Distant metastasis was the predominant recurrence pattern in the overall (45/58, 77.6%) and matched (33/44, 75.0%) cohorts. LPND without nCRT is effective and sufficient in preventing local recurrence in patients with LPN metastases. Future prospective randomized controlled studies are warranted to confirm these findings. Since systemic metastasis is the predominant recurrence pattern in patients with LPN metastasis post-LPND, improved perioperative systemic chemotherapy is needed to prevent micrometastasis.